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Abstract
Histones are positively charged nuclear proteins that facilitate packaging of DNA
into nucleosomes common to all eukaryotic cells. Upon cell injury or cell signalling
processes, histones are released passively through cell necrosis or actively from
immune cells as part of extracellular traps. Extracellular histones function as microbi-
cidal proteins and are pro‐thrombotic, limiting spread of infection or isolating areas
of injury to allow for immune cell infiltration, clearance of infection and initiation of
tissue regeneration and repair. Histone toxicity, however, is not specific to microbes
and contributes to tissue and end‐organ injury, which in cases of systemic inflamma-
tion may lead to organ failure and death. This review details the processes of his-
tones release in acute inflammation, the mechanisms of histone‐related tissue
toxicity and current and future strategies for therapy targeting histones in acute
inflammatory diseases.
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1 | INTRODUCTION
Histones were first described by Albrecht Kossel in 1884 as his-
tidine‐rich peptones derived from the nuclear component of avian
red blood cells1; he was awarded the Nobel Prize in Physiology or
Medicine for this and other work on the nucleus of cells in 1910.
Histones are highly conserved across all eukaryotic cells,2 and act as
nuclear chaperone proteins, interacting with nucleic acids due to
their highly positive charge3 from lysine and arginine residues. Each
nucleosome particle consists of 147 base pairs of DNA, wrapped in
1.7 turns around a protein octamer of core histones (H2A, H2B, H3
and H4), further compacted by linker histones (H1 and/or H5).4
Numerous post‐translational modifications of histones have been
identified, including acetylation, methylation, phosphorylation, ubiq-
uitylation, sumoylation, ADP ribosylation, deimination and proline
isomerization.5 In normal cell function, these alter the nature of the
histone‐DNA interaction and allow transcription to occur. More
recently, controlled histone degradation has been described in neu-
trophils leading to chromatin decondensation and release of genomic
DNA laced with granular proteins as neutrophil extracellular traps
(NETs).6,7 These meshwork‐like structures promote intravascular
thrombosis,8 limit spread of microorganisms, encourage cancer
metastasis9 and cause direct injury to adjacent cells.10
This review details what is known about the role of histones as
alarmins or DAMPs (damage‐associated molecular patterns), processes
leading up to active histone release as principle components of NETs,
mechanisms of injury related to extracellular histones and therapeutic
strategies for histone detoxification in acute inflammatory conditions.
2 | HISTONES AS DAMPS
Among the earliest recognized and better‐described ways in which
histones exacerbate cellular injury is in their role as alarmins or
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DAMPs. Histones released passively from necrotic cells (or actively
by other modes of cell death including NETosis) act on adjacent cells
and circulating immune cells via pattern recognition receptors to
effect specific biological activity. In in vivo systems, these effects
can be difficult to study, as histones are co‐released with nuclear
DNA and other nuclear DAMPs such as HMGB1 (high mobility
group box protein 1), each with their individual activities. Indeed, the
mechanism of cell necrosis has significant impact on the kinetics of
nuclear DAMP release,11 and nuclear DAMPs acting as complexes
have been reported to exert different activities compared to protein
isolates.12 Furthermore, where purified histones injected into experi-
mental animals are lethal within minutes,13 necrotic cell death
releases nucleosomes (ie: histone‐DNA complexes) which overall
appear to be less toxic.14 Indeed a study injecting similar doses of
nucleosomes in mice makes no mention of toxicity,15 and others
have demonstrated cofactors such as HMGB1 responsible for the
immune‐stimulatory effects of nucleosomes.16 Only through the
interplay of plasma proteases and nucleases including DNAse1 and
factor VII activating protease does nucleosome decondensation
occur17; however, this also degrades the histone component and lim-
its cytotoxicity.18 These effects may have significant implications for
in vitro signalling studies using recombinant proteins, as effects of
isolated nucleosome components may not become apparent in this
setup.
Fragments of cell membrane and nuclear proteins also interact
with complement proteins and complement cascade regulators to
facilitate cell turnover and clearance.19 An important regulator of
nucleosome toxicity appears to be factor H of the family of comple-
ment regulator proteins. Factor H is actively internalized by apop-
totic cells, where it leads to C3 complement activation and cell
surface expression, as well as enhanced nucleosome clearance and
phagocyte cytokine‐release response to nucleosomes.20 Cells under-
going secondary necrosis can thereby elicit a targeted pro‐inflamma-
tory response.21
Once released from the nucleosome, extracellular histones exert
their injurious effects in three ways summarized in Figure 1: (a) by
acting as chemokines or inducing chemokine release; (b) by inducing
cytokine release and/or apoptosis of adjacent cells and leukocytes;
and (c) through direct cytotoxicity.
2.1 | Chemoattractant effects
Histones are both directly chemoattractant, induce release of
chemokines from adjacent cells and induce activation of vascular
endothelium to promote adhesion and trans‐migration of leukocytes.
Direct chemoattractant effects have been demonstrated in vitro
using hepatocellular carcinoma cells. Histone‐induced migration of
these cells is dependent on the activation of the MAPK/ERK/NF‐kB
pathway via TLR4 (toll‐like receptor 4).22 Similarly, histones induce
secretion of chemokines CXCL9 and CXCL10 from human mono-
cytes and CXCL10 co‐localizes with extracellular histone H4 in
necrotic (but not healthy) tissue.23 Extracellular histones H3 and H4
F IGURE 1 Immunostimulatory effects of passively released histones acting as damage‐associated molecular patterns
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(but not H1 or H2A/H2B) also activate vascular endothelial cells to
increase cell surface expression of E‐selectin, ICAM‐1 and VCAM‐1,
thereby increasing leukocyte adhesion, rolling and transmigration in
a TLR9‐dependent manner.24 In higher concentrations, these his-
tones are toxic to the endothelium and represent a putative mecha-
nism for pulmonary haemorrhage and ARDS in sepsis13 or
pancreatitis.25 Histones acting on endothelial cells via TLRs 2 and 4
also activate NF‐kB and AP‐1 pathways to induce tissue factor
expression,26 thereby creating a pro‐thrombotic milieu contributing
to the microvascular thrombosis seen in many acute inflammatory
diseases. Together, these effects describe the positive feedback
loop that can lead to necroinflammation—where the death of
relatively few cells induces further injury through inflammatory cell
recruitment leading to organ failure, especially within the liver and/or
kidney.27
2.2 | Pattern recognition receptor responses
The intracellular signalling pathways of extracellular histones as
DAMPs acting via TLRs2/4/9, MyD88, NF‐kB and the NLRP3 inflam-
masome have been well documented and recently reviewed.28-30
Functionally, histones injected into the renal artery of rats induced
necroinflammation as well as IL‐6, TNF‐α and iNOS release.31 These
effects were reduced in TLR2/4 knock‐out mice and more pro-
nounced following LPS priming, which increased TLR2/4 mRNA tran-
scription. Low doses of histone H3 (10 μg/mL) have been shown to
induce release of IL‐6 and IL‐8 in ARPE‐19 cells, as well as lead to
the phosphorylation of ERKs, p38 MAPK and JNK and inhibition of
these kinases all resulted in reduced cytokine release.32 Higher doses
(50 μg/mL), however, led to cell death in a manner that could not be
inhibited using signalling kinase inhibitors. Histones also exacerbate
ischaemia/reperfusion injury by a TLR9/MyD88‐dependent mecha-
nism and enhance extracellular DNA‐mediated activation of TLR9 in
immune cells.33 Further to their effect on TLRs, histones also appear
to induce IL‐1β secretion and activation via an NLRP3/ASC/caspase1‐
dependent mechanism, leading to neutrophil recruitment to sites of
inflammation.34 Critically, induction of leukocyte cytokine production
and release is not dependent on free, circulating histones; nuclear
material within blebs from apoptotic cells can induce similar stimula-
tory effects within resident or infiltrating phagocytes.35
3 | HISTONE PROCESSING AND ACTIVE
RELEASE DURING NETOSIS
3.1 | Signal recognition
A large number of different signals have been shown to be able to
induce NET formation, including bacteria,36,37 viruses,38 yeasts,39,40
parasites,41 organic crystals,42 non‐organic matter,43 cytokines44 and
cellular breakdown products including nuclear DAMPs.45,46 In order
to detect such a variety of signals, there is overlap and convergence
of receptor pathways. This may explain some variability in early
genetic knock out studies when defining which receptor is critical in
mediating NET release. It would seem molecular pattern‐related NET
release is mediated predominantly through TLRs 2, 4 and 9,31,46,47
immune complex‐related NET release is mediated via Fc receptors
and MAC‐a48 and larger pathogens or inorganic matter lead to
NETosis though size. The inability to phagocytose large particles
within a given time appears to drive neutrophils to autodigest and
release NETs in a process dependent on dectin‐1.49 While many sig-
nals leading to NETosis may make this an unlikely therapeutic target,
it suggests that blocking destructive NETosis in sterile inflammation
is possible without affecting a potentially beneficial antimicrobial
response.
3.2 | Signal transduction
Following signal detection, there are three critical steps leading to
NET release: phagocyte oxidase/nicotinamide adenine dinucleotide
phosphate‐oxidase (PHOX/NADPHO) activation, nuclear protease
translocation and histone deimination (Figure 2).
Involvement of PHOX/NADPHO is illustrated by patients with
chronic granulomatous disease, an inherited defect in PHOX activity,
who are unable to produce NETs when stimulated with phorbol 12‐
myristate 13‐acetate (PMA).50 This in turn leads to a clinical picture
of recurrent and/or persistent infections, in particular with fungal
pathogens. Impressively, there has been a successful report of gene
therapy, where an 8‐year‐old boy was treated with a retroviral vec-
tor containing a functional gp91 (PHOX subunit) gene, resulting in
neutrophils regaining the ability to NETose and leading to a termina-
tion of an intractable Aspergillus nidans infection.51 Experimentally,
inhibition of NADPHO or myeloperoxidase (MPO) effectively inhib-
ited NETosis stimulated by PMA, whereas inhibition of mitochondrial
respiration or superoxide dismutase did not.52 PHOX/NADPHO is
itself activated by protein kinase C (PKC). Pan‐activation of PKC iso-
forms using PMA or the di‐acyl glycerol analogue 1‐oleoyl‐2‐acetyl‐
sn‐glycerol effectively stimulates NETosis.53 Specific inhibition of
PKC isoform β inhibits both reactive oxygen species (ROS) produc-
tion by PHOX and NETosis; however, there are conflicting reports
on whether PKCζ is also able to inhibit NETosis.54 There are increas-
ing reports of NADPHO‐independent NETosis, such as via the Rous
sarcoma (src) kinase family in response to chemokine receptors
(CXCR2) activation55 or via unspecified pathways following high‐
dose uric acid stimulation.56 These reports highlight the deficiencies
of investigating NETosis exclusively using PMA as the stimulant and
demonstrate that while PKC activation is sufficient for the induction
of NETosis, it is not the only pathway.
Histone deimination by peptidyl‐arginine transferase 4 (PAD4) is
an essential step in NET release.57 PAD4 targets methyl‐arginine
residues, reducing methylation and increasing citrullination on
H4Arg3 and H3Arg2, 8 and 17 in HL‐60 cells58 over a time scale of
15 minutes to 2 hours, in a manner independent of caspase activ-
ity.59 These same post‐translational modifications are amongst the
most immunogenic histone modifications seen in serum from
patients with systemic lupus erythematosis,60 and levels of circulat-
ing nucleosomes and citrullinated histone H3 correlate with disease
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severity in acute inflammatory conditions including sepsis,61
trauma62 and pancreatitis.63 Genetic deletion of PAD4 leads to an
inability of neutrophils to release NETs in response to calcium iono-
phore treatment or lipopolysaccharide (LPS),64 and pharmacological
inhibition of PAD4 inhibits NET formation in murine and human neu-
trophils.65 Overexpression of PAD4, on the other hand, has been
shown to cause histone hypercitrullination, nuclear decondensation
and release of NET‐like structures in an osteosarcoma cell line.66
Nuclear translocation of granular proteases is the next step
towards NET release. Neutrophil azoruphilic granules contain neu-
trophil elastase (NE), proteinase 3 (PR3) and cathepsin G (CG); how-
ever, only NE is translocated to the nucleus and neither inhibition of
PR3 nor CG can prevent this translocation.7 Furthermore, the pro-
cess does not appear to be mediated by fusion of granules with the
nucleus, but rather NE dissociates from the granular membrane in a
ROS‐dependent manner, before degrading cytosolic actin, arresting
actin dynamics and translocating across the nuclear membrane using
specific translocation mechanisms.67 Binding of nucleic acid by pro-
teases initiates a process of degradation of nuclear binding pro-
teins68 and controlled integration of MPO into the forming NET.
Nuclear NE leads to early degradation of linker histone H1, followed
by core histone H4 which coincides with nuclear chromatin
decondensation.7 Histone H3 appears to be resistant to degradation
in intact nuclei, but not in purified form, suggesting one of the pur-
poses of post‐translational modification is to render histone H3
resistant to NE‐related degradation. This offers novel targets for
therapy that have not yet been exploited.
The pathway described above is the best described due to the
use of PMA as experimental stimulant of NETosis. In this experimen-
tal setup, the three steps are sequential; however, there have been
recent reports of NET‐like structures being released rapidly (min-
utes), by budding of DNA/histone/protease‐containing vesicles from
the nucleus followed by active exocytosis of NET‐containing vesi-
cles.69,70 This potentially bypasses most of the mechanisms
described above and requires further study.
3.3 | Autophagy
Although most studies support the conclusion that autophagy is
essential for NETosis,71,72 inhibition of mammalian target of Rapamy-
cin (mTOR), a regulatory and inhibitory protein complex, has been
reported to reduce NETosis stimulated by bacterial LPS.73 Stimula-
tion of human neutrophils with vasculitis‐associated antibodies led
to massive vacuolization, increased LC3BI degradation and could be
F IGURE 2 Signalling cascade leading to neutrophil extracellular trap release in murine and human neutrophils
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reduced with the inhibitors of autophagy 3‐methyladenine (3MA)
and LY294002.74 Similarly, LC3B containing vacuoles were observed
preceding NETosis in LPS or septic plasma‐induced NETosis in
human neutrophils which was also effectively inhibited by 3MA and
bafilomycin A1.75 Knock down of phosphatase and tensin homo-
logue deleted on chromosome 10 (PTEN), a potent regulator of
autophagy, reduced PMA‐induced NETosis in HL‐60 cells and
overexpression increased it.76 PKC has been shown to stimulate
autophagy which in response to certain stimuli can be independent
of mTOR, offering a potential explanation for this discrepancy.77
Figure 2 demonstrates how different stimuli resulting in NETosis can
have differential effects on autophagy.
4 | MOLECULAR BASIS OF HISTONE ‐
RELATED CELLULAR AND TISSUE INJURY
4.1 | Effects of concentration and histone type on
different cells and/or tissues
A wide variety of organisms actively release histones and histone
degradation products as microbicidals (histone‐derived antimicrobial
peptides; HDAP). Table 1 records a list of HDAPs, the species of ori-
gin and purported mechanism of antimicrobial action. The mecha-
nisms of action appear to divide into membrane permeabilizing
effects or DNA‐binding and disruption of transcription, which is why
some HDAPs are also under investigation for the treatment of can-
cer. Full length core histones (H2A, H2B, H3 and H4) have shown
antimicrobial activity in vitro78 in animal79 and human80 physiology
and have the ability to neutralize bacterial endotoxin.
Cellular injury mediated by extracellular histones has been
described experimentally or in human disease of the lung,94 heart,95
liver,96 kidney31 and vascular endothelium.62 Table 2 details the
effects of extracellular histones observed in specific cell types.
Breakdown of DNA in NETs with DNAse only partially amelio-
rates NET‐related toxicity, as it does not affect the histone compo-
nent.125 Concentrations below 10 μg/mL seem to have a signalling
function and can induce calcium transients in cells.126 Concentra-
tions greater than 10 μg/mL (or 20 μg/mL in the presence of serum)
induce cell death by an uncertain mechanism, which may involve the
formation of non‐specific cationic pores in cell membranes.127,128
Concentrations above 100 μg/mL cause rapid necrosis.
Core histones H3 and H4 are most frequently reported to
increase in plasma from sepsis patients as well as experimental sep-
sis and therapeutic administration of antibodies to these histones
improve outcomes in these models.102,129,130 It is conceivable that
histone citrullination as described above renders these less suscepti-
ble to degradation and easier to detect, creating a publication bias.
As core histones oligomerize readily with each other in solution131
and will surely rapidly do so upon histone release from any cell type,
it is difficult to dissociate toxicity of individual histones from each
other in biological systems. When used in in vitro studies, recombi-
nant histones H2A and H2B were also able to induce cellular cur-
rents126 or activate thrombin.122
4.2 | Calcium/ionic pore effects
The interaction of histones with cell membranes is heavily reliant on
charge. Positively charged histones preferentially bind anionic phos-
pholipids such as cardiolipin or phosphatidylserine, but not zwitteri-
onic phospholipids like phosphatidylcholine.132 Furthermore, adding
negative charge (eg, a phosphate head group as in phosphatidylinosi-
tol bis‐phosphate) increases the binding capacity of histones as mea-
sured by calorimetry.128 Histones have also been shown to expose
phosphatidylserine on the surface of red blood cells in a dose‐depen-
dent manner47; however, it is unclear whether this is as a result of
altering flippase kinetics or via induction of apoptosis pathways.
Once integrated, histones induce permeabilization of membranes to
cations, disruptions of cellular calcium signalling112 and cell death by
necrosis. Negatively charged acute‐phase proteins (such as C‐reac-
tive protein, CRP),14 DNA,128 innate polysaccharides (heparin)120 or
synthetic macromolecules126 compete with membrane phospholipids
and prevent histone integration and toxicity. Bactericidal properties
TABLE 1 Summary of histone‐derived anti‐microbial peptides (HDAPs), their species of origin and mechanism of action
Source histone HDAP Species of origin Mechanism of action References
H1 Full length Coho salmon (Oncorhynchus kisutch) Synergism with flounder pleuricidin.
Mechanism unknown
[81]
H2A Hipposin Atlantic halibut (Hippoglossus hippoglossus L.) Membrane permeabilization [82,83]
Buforin I, II, III Asian toad (Bufo bufo gargarizans) DNA/RNA binding and disruption of
cellular functions
[84,85]
Acipensins Russian sturgeon (Acipenser gueldenstaedtii) Outer membrane permeabilization [86]
Himanturin Round whip ray (Himantura pastinacoides) Unknown [87]
Abhesin Disk abalone (Haliotis discus discus) Unknown—possible inhibitor of transcription [88]
Parasin I Catfish (Parasilurus asotus) Membrane permeabilization [89,90]
H4 Full length American cupped oysters (Crassostrea virginica) Unknown [91]
Histogranin Cow (Bos taurus) DNA gyrase inhibitor [92]
MrH4 Freshwater giant prawn (Macrobrachium rosenbergii) Unknown [93]
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of histone fragments are dependent on their ability to form amphi-
pathic α‐helices—potentially membrane spanning domains—however
no such structural analyses have been performed on mammalian cells
to date.89
4.3 | Effects on coagulation
The ability of NETs and histones to influence the coagulation
cascade and actually initiate venous thrombosis8,133,134 is the most
recent detail in the emerging field of NETosis research. Clinically,
circulating nucleosomes are independent prognostic markers of
disseminated intravascular coagulopathy (DIC)135 and some coun-
tries, notably Japan, are actively promoting the use of anticoagulants
as histone detoxification agents in DIC.136 Positive correlations
between histone levels and coagulopathy can also be seen in trauma
patients137 and patients with sepsis.129
Figure 3 summarizes the effect of histones and NETs on the
coagulation cascade. Histones act synergistically to produce a pro-
found pro‐coagulant drive. Histones are able to induce platelet
aggregation and factor V/Va expression and prothrombinase activity,
leading to thrombin activation independent of the intrinsic coagula-
tion pathway.122 Histones also inhibit thrombomodulin and protein
C activation,138 an effect most pronounced with histones H3 and
H4, thus reducing a natural thrombin inhibitor system. Furthermore,
histone H4 binding promotes thrombin autoactivation, probably by
fixing the prothrombin molecule in a conformational state conducive
to proteolytic attack.139 The only exception is linker histone H1,
which has been shown to reduce thrombin activation and prolong
TABLE 2 Summary of effects of histones on different cell types of epithelial, endothelial and mesenchymal origin seen in in vitro and
ex vivo experiments
Cell type Effects of histones in vitro or ex vivo Effective therapies
Epithelial
A549,97,98 BEAS‐2B,99 LA‐4,94 MLE‐12,94 mouse type
II pneumocytes,98 L02 hepatocytes,100 CHO‐K1,101
CHO‐A745101
Calcium influx, cytokine (IL‐1β, IL‐6, IL‐10, TNFa)
production (A549, BEAS‐2B, LA‐4) and cell death (PI/
LDH; all cell types)
Anti‐histone antibodies,
APC, heparin, polysialic
acid, CIINH
Pancreatic acinar cells102,103 Trypsin/Chymotrypsin activation, p‐STAT3/t‐STAT3 up‐
regulation, cell death (PI)
Polysialic acid
HEK293,96,104 parietal epithelial cells,105 podocytes105 Up‐regulated TLR2 and TLR4 expression, APC generation
Endothelial
HPMEC,62,98 MLVEC106 Cell death (PI/LDH) Anti‐histone antibodies,
APC, heparin, CIINH
HCAEC107 Up‐regulation of tissue factor mRNA and extression and
translation, NF‐kB/AP‐1 activation
EA.hy926,13,14,26,62,108,109 HUVEC13,14,62,107,109-111 Calcium influx, IkB depletion, p38MAPK/NF‐kB/AP‐1
activation, tissue factor and vWF generation/release, cell
death (PI/AnnexinV binding)
Anti‐histone antibodies,
APC, heparin, polysialic
acid, CRP, MBP‐p33,
PTX3
Glomerular endothelial cells105 TNFa mRNA expression, cell death (MTT) Anti‐histone antibodies
Mesenchymal
Murine cardiomyocytes,112 HL‐1 cardiomyocytes113 Cytosolic ROS production, calcium entry, mitochondrial
impairment, reduced contractility, cell death (PI)
Peripheral neutrophils,46,62 HL‐60101 IL‐6 production, NETosis, cell death (PI) Anti‐histone antibodies,
IAIP, HMW‐HA
Peripheral monocytes,23,114 MM6,115 U937,100 THP‐
1114
Cytokine production (IL‐1β, IL‐6, IL‐8, IL‐10, TNFa,
CXCL10), cell death (PI/LDH), factor Xa/tissue factor
generation
Anti‐histone antibodies,
heparin, CRP
Murine peritoneal macrophages,116 RAW264.7,102,107
Kupffer cells,33,96 J774 macrophages105
Inhibited clearance of other immune cells, HMGB1
secretion, TNFa production, increased tissue factor
expression, vWF/angiopoietin‐2/P‐selectin release
APC
Human peripheral DCs,34 human monocyte‐derived
DCs,117 murine BMDCs105,118
TNFa production, NLRP3 protein up‐regulation,
mitochondrial membrane dysfunction
Anti‐histone antibodies,
APC, heparin
Human peripheral lymphocytes119 Apoptosis, p38‐MAPK phosphorylation, mitochondrial
dysfunction, reduced bcl2 expression, caspase‐3
activation
Platelets14,101,108,120-123 Calcium influx, platelet aggregation, thrombin generation,
P‐selectin/factor Va expression
APC, heparin, CRP, HAS,
IAIP, HMW‐HA
Human erythrocytes47,108,124 Haemolysis, procoagulant APC, heparin, MBP‐p33
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clotting times140; this mechanism is likely insignificant in acute
inflammation, as histone H1 is amongst the first nuclear proteins to
be degraded in the process of NETosis.
The presence of DNA in NETs also allows activation of the
intrinsic coagulation pathway, demonstrated by NET‐enhanced
thrombin generation in platelet‐poor plasma, reduced by factor XII/
factor XI depletion or DNAse treatment.141 DNAse treatment in pla-
telet‐rich plasma further increases thrombin generation, indicating
differential effects of histones and NETs in different microenviron-
ments. The addition of histones and DNA also increases fibrin fibre
thickness, clot stability and delayed clot lysis142 as well as reducing
anti‐thrombin‐mediated thrombin inactivation and plasmin activity.143
In in vivo systems, the interplay between von Willebrand factor
(vWF), platelets and neutrophils anchors neutrophils to otherwise
healthy vessel walls and permits NETing neutrophils to initiate clot
formation,125,144 with propagation that may occur or be enhanced
by the mechanisms described above. Deficiencies in degradation of
vWF produce clinical microangiopathies (eg, thrombotic thrombocy-
topenic purpura), the severity of which is also closely correlated with
circulating NET components in humans.145
5 | THERAPEUTIC STRATEGIES FOR
HISTONE DETOXIFICATION IN PATHOLOGY
Histone toxicity is dependent on electrostatic membrane interaction
with target cells. A number of innate and synthetic substances have
demonstrated the ability to inhibit histone‐related toxicity based on
surface charge alone, including plasma proteins (albumin,123 CRP14),
polypeptides (polyglutamic acid126) and polysaccharides (heparin/hep-
aranoids,111,146 polysialic acid,147 bacterial O‐antigen148). Elevated
histone‐degrading activated protein C (APC) levels are associated
with better outcomes in sepsis115,149 and trauma patients137; APC
therapy is being evaluated for treatment of sepsis150 and pancreati-
tis.151 The effects of histones and NETs on the coagulation cascade
can be overcome by therapy with thrombomodulin121 or tissue plas-
minogen activator (tPA),143 but the clot‐stabilizing effects of DNA in
NETs must be overcome, which is well illustrated by the finding that
DNAse therapy in addition to tPA is more effective than either ther-
apy alone.152
In models of sterile and infective acute inflammatory diseases,
administration of histones exacerbates end‐organ injury consistently
(Table 3). Similarly, damaging effects are at least partly ameliorated
by the application of histone‐targeted or histone‐specific therapies.
6 | CONCLUSIONS
Histones and histone fragments are parts of an ancient antimicrobial
mechanism conserved throughout eukaryotic species. In mammals,
packaging of histones into NETs and interaction with the coagulation
cascade presents an effective mechanism of limiting the spread of
microorganisms and concentrating microbicidal peptides at a site of
infection, but this comes at a cost of injury to adjacent tissue. In
acute systemic inflammatory conditions, such as sepsis and trauma,
systemic release of histones exacerbates micro‐circulatory
F IGURE 3 Interaction of histones and DNA with coagulation cascade to promote thrombosis
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TABLE 3 Summary of effects of extracellular histones observed in in vivo models
Experimental model Observations
Effective histone‐based treatment
strategies References
Sepsis
Bacterial
lipopolysaccharide
(1‐40 mg/kg i.p/i.v.)
Elevation of circulating histones (including cit‐
H3), leukocyte/platelet depletion/DIC; lung:
neutrophil margination; endothelial
vacuolization, intra‐alveolar haemorrhage and
thrombosis; renal: cytokine/chemokine
release, tubular apoptosis, neutrophil
infiltration, death
APC, anti‐histone antibodies (H1, H4, pan‐
histone), heparin (unfractionated or anti‐
thrombin activity depleted), PTX3, PLD2
inhibition
[13,31,95,109,
111,153-158]
Caecal ligation and
puncture
Elevation of circulating histones, leukocyte
apoptosis; lung injury; reduced cardiac
output, left ventricular stroke volume and
blood pressure (systolic and diastolic);
cytokine release and injury of liver, kidney
and spleen; death
Neutrophil depletion, Complement (C5aR1/
C5aR2) receptor knock‐out, anti‐histone
antibody, non‐anticoagulant heparin,
PAD4 inhibition (Cl‐amidine)
[13,109,112,119,
154,157,159]
MRSA (1‐10 × 107 i.v.) Bacterial dissemination in blood, liver, spleen,
kidney and lung, with associated organ injury
Neutrophil depletion, unfractionated
heparuin, DNAse I, vWF inhibition, PAD4
k/o, NE k/o or inhibition
[125]
Lung injury
Bacterial
lipopolysaccharide
(1‐40 μg/animal i.t.)
Elevation of circulating histones; Pulmonary
neutrophil infiltration, NETosis, elevated NE
activity, abnormal gas exchange; death
Anti‐H4, aspirin, tirofiban, DNAse I,
neutrophil depletion, C5a k/o
[94,97,160]
Intra‐nasal influenza A
virus (102 PFU) or
Streptococcus
pneumoniae (106 PFU)
Elevation of circulating histones; pulmonary
chemokine/cytokine release and inflammatory
infiltrate
C1 esterase inhibitor [98]
Intra‐tracheal irritant
(HCl, 2 μL/g i.t. 0.01‐
0.5 mol/L; Bleomycin
2.5 U/kg i.t.)
Elevation of circulating histones and DNA
complexes; elevated pulmonary MPO/LDH
activity, neutrophil infiltration, inter‐ and
intra‐ alveolar oedema, reduced arterial
oxygenation
Anti‐H4, heparin (unfractionated or N‐
acetyl), C1 esterase inhibitor
[98,99,161]
Liver injury
Ischaemia/reperfusion Increase in hepatic H3 and H4 and cytokine
release; increase in circulating histone‐DNA
complexes
Anti‐H3/H4, PAD4 inhibitor [33,46,162]
D‐galactosamine (300‐
700 mg/kg i.p.) plus LPS
(10‐40 mg/kg i.p.)
Hepatic leukocyte infiltration, hepatocellular
apoptosis/necrosis; systemic cytokine release
and transaminase elevation; death
Anti‐H4, antithrombin activity‐depleted
heparin
[100,163]
Acute pancreatitis
Caerulein (50 μg/kg/h × 4
or 12 i.p.)
Elevation of circulating histones; pancreatic
necrosis
[163]
Taurocholate (3.5%‐5%
intra ductal)
Elevation of circulating and intra‐pancreatic
histones and chemokines/cytokines; NETosis
and inflammatory cell infiltrate within
pancreas
Thrombin‐derived host defence peptides [63,103,164]
L‐arginine (4 mg/kg i.p.) Elevation of pancreatic histones, neutrophil
infiltrate and oedema; pancreatic necrosis;
death
Anti‐H3, thrombin‐derived host defence
peptides
[102,102,164]
Systemic administration of histones
Calf‐thymus histones
(0.75‐75 mg/kg i.v.)
Platelet depletion, haemolysis, elevation of
vWF, fibrin and thrombin as well as systemic
cytokines; prolonged bleeding time;
pulmonary oedema, haemorrhage and
microvascular occlusion; death
Heparin (unfractionated or O‐desulfated),
C‐reactive protein, soluble
thrombomodulin, anti‐histone antibody
[14,101,104,108,110,
113,120,121,165]
Recombinant H3
(25‐100 mg/kg)
Leukocyte and platelet depletion; liver injury;
death
Heparin (unfractionated and/or low
molecular weight)
[166]
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thrombosis, worsens tissue perfusion and contributes significantly to
organ injury. Recognition of this phenomenon may allow targeted
therapy, limiting systemic injury and improving survival.
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